Community
The Bank for International Settlements thinks that financial instruments should be classified like medicinal drugs to protect investors and prevent firms from excessive over-indulgence in potentially lethal or toxic products.
"The safest securities would, like non-prescription medicines, be available for purchase by everyone," says the bankers' bank in its annual report. "Next would be financial instruments available only to those with an authorisation, like prescription drugs; another level down would be securities available only in limited amounts to pre-screened individuals and institutions, like drugs in experimental trials."
I like the idea, but it would have to be a two-way street, with regulatory scrutiny applied to the financial pharmacies manufacturing the drugs. In this way, institutions suffering from outbreaks of hubris or exhibiting symptoms of irrational exuberance - getting high on their own supply in street parlance - would have their access to exotic class A securities severely restricted.
This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author.
Nkahiseng Ralepeli VP of Product: Digital Assets at Absa Bank, CIB.
10 March
Nicholas Holt Head of Solutions and Delivery, Europe at Marqeta
07 March
Ivan Nevzorov Head of Fintech Department at SBSB FinTech Lawyers
Kate Leaman Chief Analyst at AvaTrade
06 March
Welcome to Finextra. We use cookies to help us to deliver our services. You may change your preferences at our Cookie Centre.
Please read our Privacy Policy.